Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: January 25, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 1.08 billion |
|
Revenue Forecast in 2030 |
US$ 2.76 billion |
|
CAGR |
11% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Drug class, Distribution channel and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market was valued at US$ 1.08 billion in 2021 and is expected to register a revenue CAGR of 11% to reach US$ 2.76 billion by 2030.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market Fundamentals
Autosomal dominant polycystic kidney disease (ADPKD) is the most common type of polycystic kidney disease (PKD). This disorder affects 1 in every 400 to 1,000 individuals and is the most common hereditary kidney illness. The term autosomal dominant refers to the fact that the PKD gene mutation or defect can be inherited from only one parent. ADPKD is caused by two distinct gene mutations, according to researchers. Most patients with ADPKD have PKD1 gene deficiencies, while one in every six or one in every seven individuals with ADPKD has a defective PKD2 gene.
ADPKD is caused by a genetic flaw that impairs the normal growth of some kidney cells, resulting in cyst formation. ADPKD is known to be caused by mutations in one of two distinct genes - PKD1, which accounts for 85% of instances, and PKD2, which accounts for 15% of cases. Both types have the same symptoms; however, PKD1 associated variant is more severe. If one of the parents carries the defective PKD1 or PKD2 gene, the child has a 50% chance of inheriting ADPKD.
In ADPKD, the genotype-phenotype connection is not fully known. The condition is associated with a wide range of phenotypes, ranging from newborns with enormous cystic kidneys to those whose renal function remains acceptable well into old age. The identification of the afflicted locus (PKD1 vs. PKD2 mutation), the allelic variant (truncating, non-truncating, or hylomorphic), the timing of gene inactivation, mosaicism, and genetic background are important factors in determining this variability. Men's phenotypes can be slightly more severe than that of women.
Mutations in PKD1 or PKD2 reduce intracellular calcium, increase cyclic adenosine monophosphate (cAMP), activate protein kinase A, and increase the susceptibility of collecting duct main cells to the steady tonic impact of vasopressin. Calcium signaling disturbance, along with increased cAMP signaling, activates downstream signaling pathways that are responsible for poor tubulogenic cell proliferation, increased fluid secretion, and interstitial inflammation. Additionally, symptoms and signs include flank and stomach pain, hematuria, and hypertension. CT scan or ultrasonography is used for the diagnosis. Prior to renal failure, treatment is symptomatic, followed by dialysis or transplantation.
[395730]
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market Dynamics
Increase in the emphasis on early diagnosis and technological advances in diagnostic processes have lowered the number of undetected cases across developed and developing countries. Thus, increase in the number of diagnosed ADPKD cases offers an opportunity for companies to provide innovative medicines, which in turn, fuels revenue growth in the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market.
Progress made in establishing the genetic etiology of ADPKD, non-invasive monitoring, and forecasting disease progression is likely to benefit disease management. Pre-symptomatic diagnosis and its application in the care and management of patients contribute to the revenue growth of the autosomal dominant polycystic kidney disease (ADPKD) therapeutics market. Moreover, the robust and active ADPKD pipeline, with several therapies being developed at various stages, is propelling the autosomal dominant polycystic kidney disease (ADPKD) therapeutics market's revenue growth. Additionally, the identification of biomarkers for the early detection of ADPKD patients at high risk of advancement is likely to aid in improved patient management and prevention of disease progression.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market Ecosystem
The global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market is analyzed from three perspectives: drug class, distribution channel, and region.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market by Drug Class
[4213113]
Based on the drug class, the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market is segmented into vasopressin antagonists, ace inhibitors, angiotensin II receptor blockers, and others.
The vasopressin antagonists segment dominates the market. Treatments for ADPKD may reduce morbidity and death owing to disease-related complications. However, they do not slow disease progression. Tolvaptan, a selective vasopressin V2 receptor antagonist, improves pain and delays the increase in kidney volume (a surrogate measure for disease progression) in ADPKD patients with maintained renal function.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market by Distribution Channel
Based on the distribution channel, the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others.
The hospital pharmacies segment dominates the market, as hospital pharmacies have more operating capital to invest in cutting-edge medical technologies. Hospitals have the essential medical equipment to offer patients complete care as they are generally multi-specialty centers.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market by Region
Geographically, the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market is segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America is expected to dominate the market during the forecast period, owing to high per capita income and rising awareness about the importance of early detection of chronic renal illnesses. According to World Bank data, the annual income of individuals from the U.S. increased to US$ 69,287.5 in 2021 from US$ 63,027.7 in 2020. Furthermore, inexpensive healthcare policies, extensive drug R&D activities, expansion of the medical and healthcare industries, and drug accessibility are expected to fuel the autosomal dominant polycystic kidney disease (ADPKD) therapeutics market revenue growth in North America.
Extensive R&D activities focused on medication therapies to treat polycystic kidney disease by key businesses in Germany, Switzerland, and the U.K. are likely to drive revenue growth in the Europe market. Significant growth in the medical and healthcare industries in China, Japan, and Australia is expected to drive the Asia Pacific autosomal dominant polycystic kidney disease (ADPKD) therapeutics market in the near future. Advancements in tests and diagnosis, rising per capita income, and drug availability are expected to boost the autosomal dominant polycystic kidney disease (ADPKD) therapeutics market in the Middle East and Africa during the forecast period.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market Competitive Landscape
The prominent players operating in the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market are:
To stay ahead of the competition, the market's major competitors are focusing on extending their geographical presence and investing in product development. The use of organic and inorganic strategies by companies is expected to aid in the polycystic kidney disease treatment market revenue growth in the next few years.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market Strategic Developments
Europe is the key revenue growth region in the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market
The growing special regulatory designations and technological innovations are the major factors driving the revenue growth of the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market.
The global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market is expected to be valued at US$ 2.76 billion by 2030.
The global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market is expected to register a revenue CAGR of 11% during the forecast period from 2022 to 2030.
Otsuka Pharmaceutical Co., Ltd., Regulus Therapeutics, Palladio Biosciences, Reata Pharmaceuticals, Inc., and Galapagos NV are among the major players in the global autosomal dominant polycystic kidney disease (ADPKD) therapeutics market.
*Insights on financial performance are subject to availability of the information in the public domain